NEW YORK (GenomeWeb) – Cofactor Genomics announced today that it has partnered with cancer drug developer FLX Bio to create a novel RNA-based immuno-oncology (IO) analysis platform.

According to Cofactor, the platform — called Cofactor Paragon — will be developed using its Sigmund RNA signature analysis technology and RNA assay development expertise, along with FLX Bio's purified immune cells, validation samples, and tumor samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.

Nov
02
Sponsored by
Qiagen

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Dec
05
Sponsored by
Agilent

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.